Frontlight ResearchEarly access
Active, not recruitingNo phase
S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children
Key facts
- Who runs it
- nthalmic Pty Ltd
- Where
- China, India, and Spain7 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 441 people, planned
- Started
- 4 Aug 2023
- Expected to end
- May 2028
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- S.T.O.P® F2
- S.T.O.P® DT
- MiSight®
- Record updated
- 17 June 2026
Who can take part
- Age
- 8 years to 14 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Be between 8-14
- Have:; Read the Informed Assent; Been explained the Informed Assent; Indicated an understanding of the Informed Assent; Signed the Informed Assent
- Have their parent / legal guardian:; Read the Informed Consent; Been explained the Informed Consent; Indicated an understanding of the Informed Consent; Signed the Informed Consent
- Along with their parent / legal guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to study requirements
- Along with their parent / legal guardian, agree to maintain the visit schedule
- Agree to wear allocated contact lenses for a minimum of 5 days per week, at least 6 hours per day on days lenses are worn but not > 16 hours per day, and to remove lenses at night (i.e., daily wear only with no contact lens wear during sleep), for their duration of the study and to inform the investigator if their schedule is interrupted. Wearing time can be modified by the investigator for health reasons
- Possess wearable and visually functioning spectacles
- Be in good general health, based on the parent's / legal guardian's knowledge
- Have best-corrected high contrast visual acuity based on manifest refraction of 0.10 logMAR (20/25, 6/7.6) or better in each eye
- Meet the following criteria determined by cycloplegic autorefraction:; Spherical equivalent between -0.75 to -4.00 D inclusive; Astigmatism ≥ -1.00 D; *participants who fail astigmatism criterion with autorefraction pass astigmatism criterion if ≥ -0.75 D is measured with subjective refraction; anisometropia ≤ 1.00 D
Who cannot take part
- Participant is currently, or within 30 days prior to this study, has been an active participant in another study
- Current or prior use of ANY form of myopia control, including but not limited to:; Optical devices; Bifocal / multifocal spectacles of any type; Bifocal / multifocal contact lenses of any type; Orthokeratology of any type; Pharmacological agents; European and Indian sites: Atropine; Chinese sites: Atropine with a concentration > 0.01%. Participants who have previously used 0.01% atropine are eligible for this study provided they agree not to use 0.01% atropine for at least 30 days before baseline and at any time during the study; Pirenzepine
- Habitual use of a systemic or topical medication that may alter normal ocular findings / is known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and / or during the clinical trial
- Chinese sites: A known allergy to cyclopentolate
- A known corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections, or any other recurrent ocular infections
- Strabismus by cover test at distance (3 m) or near (40 cm) while wearing distance correction under non-cycloplegic conditions
- Known ocular or systemic disease, such as but not limited to:; Diabetes; Graves' disease; Glaucoma; Uveitis; Scleritis; Auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome, and systemic lupus erythematosus
- Any ocular, systemic, or neuro-developmental conditions that could influence refractive development, such as but not limited to:; Persistent pupillary membrane; Vitreous haemorrhage; Cataract; Central corneal scarring; Eyelid haemangiomas; Marfan's syndrome; Down's syndrome; Ehler's-Danlos syndrome; Stickler's syndrome; Ocular albinism; Retinopathy of prematurity
- Biomicroscopic that contraindicate contact lens, such as but limited to:; Neovascularisation or ghost vessels ≥ 1.5 mm in from limbus; Any active anterior segment disease that contraindicates safe contact lens wear; Clinically significant giant papillary conjunctivitis; Clinically significant abnormalities of the anterior segment, lids, conjunctiva, sclera, or associated structures; Allergic or seasonal conjunctivitis if the investigator believes it could significantly interfere with maintaining a specified wearing schedule
- A known allergy to sodium fluorescein, benoxinate, proparacaine, or tropicamide
- Participant born earlier than 30 weeks or weighed < 1500 g at birth
- Keratoconus or irregular cornea
- The investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To compare the rate of myopia progression of contact lenses utilising S.T.O.P.® technology against MiSight® contact lenses.
The 3 groups in the trial
- MiSight®Existing treatment, for comparison
MiSight® Contact Lens (Omafilcon A, 60% water)
- S.T.O.P® F2Treatment being tested
S.T.O.P® F2 Contact Lens (Ocufilcon D, 55% water)
- S.T.O.P® DTTreatment being tested
S.T.O.P® DT Contact Lens (Ocufilcon D, 55% water)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Contact Lenses Utilising S.T.O.P.® Technology Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children: A Three-year Prospective, Multi-centre, Controlled, Masked, Randomised, Non Inferiority Clinical Trial
- Record updated
- 17 June 2026